121 related articles for article (PubMed ID: 38403131)
1. Viral inactivation for pH-sensitive antibody formats such as multi-specific antibodies.
Duret A; Duarte L; Cahuzac L; Rondepierre A; Lambercier M; Mette R; Recktenwald A; Giovannini R; Bertschinger M
J Biotechnol; 2024 Mar; 384():45-54. PubMed ID: 38403131
[TBL] [Abstract][Full Text] [Related]
2. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
3. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
4. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
6. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
7. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system.
El-Ekiaby M; Sayed MA; Caron C; Burnouf S; El-Sharkawy N; Goubran H; Radosevich M; Goudemand J; Blum D; de Melo L; Soulié V; Adam J; Burnouf T
Transfus Med; 2010 Feb; 20(1):48-61. PubMed ID: 19778318
[TBL] [Abstract][Full Text] [Related]
8. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
9. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
10. Single-use technology for solvent/detergent virus inactivation of industrial plasma products.
Hsieh YT; Mullin L; Greenhalgh P; Cunningham M; Goodrich E; Shea J; Youssef E; Burnouf T
Transfusion; 2016 Jun; 56(6):1384-93. PubMed ID: 27125447
[TBL] [Abstract][Full Text] [Related]
11. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
12. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
Burnouf T; Chou ML; Cheng LH; Li ZR; Wu YW; El-Ekiaby M; Tsai KH
Vox Sang; 2013 Jan; 104(1):1-6. PubMed ID: 22758375
[TBL] [Abstract][Full Text] [Related]
13. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
14. Insights into virus inactivation by polysorbate 80 in the absence of solvent.
Chen D; Luo W; Hoffman J; Huang L; Sandefur S; Hall T; Murphy M; O'Donnell S
Biotechnol Prog; 2020 May; 36(3):e2953. PubMed ID: 31846227
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of viruses using novel protein A wash buffers.
Bolton GR; Selvitelli KR; Iliescu I; Cecchini DJ
Biotechnol Prog; 2015; 31(2):406-13. PubMed ID: 25482293
[TBL] [Abstract][Full Text] [Related]
16. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
17. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Biologicals; 2007 Oct; 35(4):349-53. PubMed ID: 17656111
[TBL] [Abstract][Full Text] [Related]
18. Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes.
McCue JT; Selvitelli K; Cecchini D; Brown R
Biotechnol Prog; 2014; 30(1):108-12. PubMed ID: 24124172
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ionic strength for X-MuLV inactivation by low pH treatment for monoclonal antibody purification.
Daya J; Cusick V; Mattila J
Biotechnol Bioeng; 2023 Jun; 120(6):1605-1613. PubMed ID: 36924035
[TBL] [Abstract][Full Text] [Related]
20. On-column virus inactivation by solvent/detergent treatment for a recombinant biological product.
Polasek D; Flicker A; Fiedler C; Farcet MR; Purtscher M; Kreil TR
Biologicals; 2023 Aug; 83():101693. PubMed ID: 37516085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
